logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Targeted Oncology cover

Targeted Oncology

IF4
Papers1219
Citations2514
Journal Papers 1215
Publication Date
delete
Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC
deleteTargeted Oncology
IF4
delete2026-10-04
delete0
PREAI
deleteAlireza Tojjari; Anwaar Saeed
deleteShare
deleteSave
Correction: Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure
deleteTargeted Oncology
IF4
delete2026-10-02
delete0
PREAI
deleteKwon Yong Tak; Hee Sun Cho; Jaejun Lee; Kyeungmo Yang; Ahlim Lee; Ji Won Han; Soon Kyu Lee; Hyun Yang; Heechul Nam; Hee Yeon Kim; Sung Won Lee; Seok-Hwan Kim; Do Seon Song; Myeong Jun Song; Jung Hyun Kwon; UIm Chang; Soon Woo Nam; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Hae Lim Lee; Pil Soo Sung
deleteShare
deleteSave
Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study
deleteTargeted Oncology
IF4
delete2026-10-02
delete0
deleteOAAI
deletePetros Grivas; Piyush K. Agarwal; Hikmat Al-Ahmadie; Terence Friedlander; Daniel M. Geynisman; Yair Lotan; Alicia K. Morgans; Fernando J. Bianco; Sreenivasa Chandana; Bruno Fang; Michael Large; Joshua J. Meeks
deleteShare
deleteSave
Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
deleteTargeted Oncology
IF4
delete2026-09-19
delete0
deleteOAAI
deleteVeronique Dieras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; Giovanna Granata; Qi Shen; Erika Hamilton
deleteShare
deleteSave
Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin
deleteTargeted Oncology
IF4
delete2026-09-16
delete0
deleteOAAI
deleteWendy Stock; Ryan D. Cassaday; Daniel J. DeAngelo; Anjali Advani; Nicola Gokbuget; Josep Ribera; Wei Jiang; Susana Pulido; Erik Vandendries; Nathan Braniff; Elias Jabbour; Hagop Kantarjian
deleteShare
deleteSave
One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis
deleteTargeted Oncology
IF4
delete2026-09-14
delete0
deleteOAAI
deleteToru Inoue; Kazuyuki Numakura; Takahiro Osawa; Sei Naito; Takuma Ishihara; Kojiro Ohba; Kosuke Ueda; Yuya Sekine; Masaharu Oki; Hirohito Naito; Haruka Miyata; Hiroshi Kikuchi; Shin Kobayashi; Shintaro Narita; Norihiko Tsuchiya; Mikio Sugimoto; Tsukasa Igawa; Toshitaka Shin
deleteShare
deleteSave
Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion
deleteTargeted Oncology
IF4
delete2026-09-12
delete0
deleteOAAI
deleteWade T. Iams; Narjust Florez
deleteShare
deleteSave
Osimertinib Plus Platinum–Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC
deleteTargeted Oncology
IF4
delete2026-09-11
delete0
PREAI
deleteAmy Zhuang-Yan; Yahiya Y. Syed
deleteShare
deleteSave
Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure
deleteTargeted Oncology
IF4
delete2026-09-01
delete0
PREAI
deleteKwon Yong Tak; Hee Sun Cho; Jaejun Lee; Kyeungmo Yang; Ahlim Lee; Ji Won Han; Soon Kyu Lee; Hyun Yang; Heechul Nam; Hee Yeon Kim; Seungwon Lee; Seok-Hwan Kim; Do Seon Song; Myeong Jun Song; Jung Hyun Kwon; UIm Chang; Soon Woo Nam; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Hae Lim Lee; Pil Soo Sung
deleteShare
deleteSave
Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A Podcast
deleteTargeted Oncology
IF4
delete2026-08-31
delete0
deleteOAAI
deleteMaryam B. Lustberg; Megan-Claire Chase; Stacey Tinianov; Kevin Kalinsky
deleteShare
deleteSave
Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies
deleteTargeted Oncology
IF4
delete2026-08-18
delete0
deleteOAAI
deleteKen Ogasawara; Rina Nishii; Yizhe Chen; Nanda Balasubramanian; Abood Okal
deleteShare
deleteSave
Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review
deleteTargeted Oncology
IF4
delete2026-08-14
delete0
PREAI
deleteRobin Grellet; Paul Rat; Olivier Facy; Nicolas Santucci
deleteShare
deleteSave
Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence
deleteTargeted Oncology
IF4
delete2026-08-12
delete0
deleteOAAI
deleteAnna Klimczak; Katarzyna Kisielewska; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
deleteShare
deleteSave
Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis
deleteTargeted Oncology
IF4
delete2026-08-07
delete0
deleteOAAI
deleteMattia Alberto Di Civita; Laura Pappalardo; Danila De Angelis; Marco Stellato; Luca Zacco; Simone Rota; Eleonora Gusmaroli; Valentina Guadalupi; Iolanda Speranza; Michela Roberto; Elena Verzoni; Giuseppe Procopio; Daniele Santini
deleteShare
deleteSave
P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
deleteOAAI
deleteHope S. Rugo; Joanne C. Ryan
deleteShare
deleteSave
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
PREAI
deleteLuis Chinea; Caroline Hauer; Khushboo Pal; Hannah L. Chang; Isaac S. Chan
deleteShare
deleteSave
Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
deleteOAAI
deleteDanny Nguyen
deleteShare
deleteSave
FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials
deleteTargeted Oncology
IF4
delete2026-08-02
delete0
PREAI
deleteLiqiong Xue; Guopei Zhu; Peiguo Wang; Kunyu Yang; Yan Sun; Weidong Li; Zhendong Li; Cuihong Jiang; Qingqing Cai; Meiyu Fang; Man Hu; Minghua Ge; Wei Zhou; Sichen Li; Ye Guo
deleteShare
deleteSave
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)
deleteTargeted Oncology
IF4
delete2026-07-29
delete0
PREAI
deleteMimma Rizzo; Sebastiano Buti; Ondřej Fiala; Lorena Incorvaia; Javier Molina-Cerrillo; Maria T. Bourlon; Wataru Fukuokaya; Fumihiko Urabe; Se Hoon Park; Karl Mayrhofer; Renate Pichler; Dora Niedersuess-Beke; Tarek Taha; Thomas Büttner; Aristotelis Bamias; Emmanuel Seront; Daniele Santini; Luciano Stumbo; Alejo Rodriguez-Vida; Francesco Massari; Fernando Sabino Marques Monteiro; Andrey Soares; Enrique Grande; Matteo Santoni
deleteShare
deleteSave
Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years
deleteTargeted Oncology
IF4
delete2026-07-26
delete0
deleteOAAI
deleteMelanie Bathon; Nele Binder; Sabrina Welland; Christoph Gerdes; Thomas Wirth; Kristina I. Ringe; Markus Quante; Arndt Vogel; Anna Saborowski
deleteShare
deleteSave